GlassScriptPhysician profile
Brian D Crosser
NPI 1700346228
$1,290.93
in general payments reported to CMS, 2019-2025
11 companies · $463 in 2025
The $463 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.64 · 2022: $187 · 2023: $260 · 2024: $354 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,076.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $389.19 | 2022-2025 | Endurant Iis, Heli-Fx Endoanchor System, Endoflip |
| Angiodynamics, INC. | $200.67 | 2023-2024 | Solero |
| Davol INC. | $159.76 | 2025 | Bard 3dmax Mesh |
| Silk Road Medical, INC. | $157.89 | 2022-2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Vertex Pharmaceuticals Incorporated | $150.38 | 2025 | |
| Boston Scientific Corporation | $125.88 | 2021-2024 | Eluvia |
| Braintree Laboratories, INC. | $29.75 | 2025 | Suflave |
| W. L. Gore & Associates, INC. | $26.80 | 2025 | Gore Synecor Biomaterial |
| Ethicon US, LLC | $19.62 | 2024 | Vistaseal, Surgiflo Hemostatic Matrix, Surgicel Nu-Knit |
| Hologic Sales and Service, LLC | $17.10 | 2025 | Magtrace |
| Tela Bio, INC. | $13.89 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Crosser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.